Semaglutide
InjectionWeight Loss
TabletWeight LossIn stock
Semaglutide tablet
A once-daily GLP-1 tablet for clinics that want an oral semaglutide option in their weight-loss program — with the intake, billing, and refill infrastructure to launch and scale it.
Dose
Once daily
Avg. loss · 68 wks
−15.1%
Format
Once-daily oral tablet
Before food
Wait 30 min before food or oral meds
Rx required
Yes — licensed provider review
Program type
Cash-pay weight-loss protocol
About the medication
Daily oral semaglutide for patients who prefer tablets
Oral semaglutide uses the same GLP-1 receptor agonist in a tablet format. In the phase 3 OASIS 1 trial, adults with overweight or obesity taking oral semaglutide 50 mg once daily lost an average of 15.1% of body weight over 68 weeks, compared with 2.4% with placebo.
- Uses semaglutide in a once-daily oral format for weight-loss protocols
- Reduces appetite and increases satiety through GLP-1 receptor activity
- Taken on an empty stomach with up to 4 ounces of water, then wait at least 30 minutes before food or other oral meds
- Good fit for clinics serving patients who want a non-injectable option
Mechanism
GLP-1 receptor agonist — appetite & satiety pathway
Delivery
Once-daily tablet swallowed whole in the morning
Administration
Empty stomach; wait at least 30 minutes before food, drinks, or other oral meds
Oversight
Every order routed through a licensed provider review
Expected results
Strong weight-loss outcomes without the weekly shot
Based on the OASIS 1 phase 3 trial (68 weeks, escalation to 50 mg daily). Real-world outcomes depend on adherence to empty-stomach dosing, titration, lifestyle changes, and individual response.
15.1%
Avg. total body weight loss
at 68 weeks, 50 mg daily dose
85%
Patients losing ≥5% weight
at week 68 in OASIS 1
54%
Patients losing ≥15% weight
at week 68 in OASIS 1
Mean change in body weight
% change from baseline · weeks 0–68
Oral semaglutide 50 mgPlacebo
At week 68
−15.1%
Oral semaglutide 50 mg
At week 68
−2.4%
Placebo
Net difference
−12.7 pts
vs. placebo
Illustrative — based on published OASIS 1 trial outcomes. Not a clinical guarantee. Compounded semaglutide formulations may vary and are prescribed off-label at provider discretion.
Dosing protocol
Standard titration schedule
Patients step up gradually to improve GI tolerability. This mirrors the oral escalation used in OASIS 1; provider-directed protocols can vary by patient and pharmacy.
- 1Weeks 1–43 mgInitiation dose used in oral semaglutide escalation
- 2Weeks 5–87 mgFirst up-titration
- 3Weeks 9–1214 mgTherapeutic ramp
- 4Weeks 13–1625 mgIntermediate escalation
- 5Week 17+50 mgTarget maintenance dose used in OASIS 1
The Turbopills stack for this program
Everything you need to run an oral semaglutide program
Pick the pieces you want. Use your own brand, your own providers, your own price — powered by a single, compliant backend.
Product website & ad landing pages
Turbopills AI Studio — ad images & videos
BetaProvider review & e-Rx
Pharmacy order routing
Refills & auto-ship
Experiments & A/B tests
BetaReady to launch
Launch a semaglutide tablet program in weeks — not quarters.
The platform ships the intake flow, billing, subscriptions, refill workflows, and the operator console your team works in. Bring your licensed providers and pharmacy partners; we wire everything into one backend so you launch in weeks, not quarters.
Marketing and educational content only. Clinical details on this page are summarized from publicly available sources to help operators scope a program — they are not medical advice, dosing instructions, or a recommendation for any individual patient. Real patient care requires a licensed provider and a compliant pharmacy partner; Turbopills provides the software that helps brands run the program around them.
Related
